However, current results are only associations in which the neuroprotective activity of AMG in PPA-induced neurobehavioral, molecular and morphological alterations in Autism-treated rats is primarily examined by the reduction of ERK1/2 levels. The gene discussed is MAPK3; the disease is autism.